Phase 4 – REVIVE

Skip to content

Search for:

Home
About
Antimicrobial Viewpoints
Conferences
- Conference calendar
- Conference recordings
Encyclopaedia
Experts
Library
Webinars

Search our library

Search for:

Use the filters below to narrow your search:

Content format

Article Definition Encyclopaedia External resource Video

Resource type

Antimicrobial Viewpoint Conference Database Funding Mechanism Guideline Infographic Organization Presentation Project Protocol/SOP Publication Scientific Journal Tool Video Webinar

Drug development

CMC Discovery Exploratory Hit-to-lead Lead-to-candidate Phase 1 Phase 2 Phase 3 Phase 4 PK/PD Preclinical development Regulatory Screening Toxicology

Indication

ABSSI Bloodstream infection Gonorrhoea HAP/VAP IAI Pneumonia SSTI STI Tuberculosis UTI

Microbe / Microbial properties

Acinetobacter baumannii Enterobacteriaceae Enterococcus faecium Escherichia coli ESKAPE Gram negative Gram positive Klebsiella pneumoniae MDR PDR Pseudomonas aeruginosa Staphylococcus aureus WHO priority pathogens XDR

Antibiotics class

Aminoglycosides Carbapenems Cephalosporins Diarylquinolines Glycopeptides Lincomycins Macrolides Penicillins Quinolones Sulfonamides Tetracyclines

Other tags

Access Diagnostics Stewardship

Advancing antibiotic R&D during the COVID-19 pandemic

New clinical trial designs for evaluation of antimicrobial agents

Best available therapy (BAT)

Suspected unexpected serious adverse reaction (SUSAR)

Serious adverse event (SAE)

Quality assurance (clinical trials)

Power (clinical trials)

Outcome, clinical trial

Observational study

Number needed to treat (NNT)

Connect

© All Rights Reserved

Search site

Search for:

© All Rights Reserved

Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy

GARDP

Website by Minthical

✕

Newsletter

Subscribe to our newsletter to stay up-to-date about our webinars, conferences and other activities.

First name *

Last name *

Email *

Organization

I accept the terms of use and privacy policies

View previous newsletter

Leave this field empty if you're human:

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy